 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
2 News |  |
| «12...6789101112131415161718 |
- | Darzalex Faspro (daratumumab/hyaluronidase) / J&J
Trial completion date, Combination therapy: TRIMM-2: A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma (clinicaltrials.gov) - Jun 18, 2020
P1b, N=100, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Oct 2021 --> Jan 2022
- ||| teclistamab (JNJ-64007957) / Genmab, J&J, Darzalex Faspro (daratumumab/hyaluronidase) / J&J
Clinical: the trial also tests subcutaneous dosing (don't know if that already started) https://t.co/TJI3cjyCZC There is also a combination trial with Daratumumab SC (Pre-treatment with dara was found to enhance Teclistamab efficacy); would be nice if both could be SC #Genmab $GMAB $JNJ (Twitter) - Jun 18, 2020
- || teclistamab (JNJ-64007957) / Genmab, J&J
How long is the infusion with teclistamab? Is it Css? Or pretty standard antibody type of infusion of 2-4hrs? (Twitter) - Jun 16, 2020
- ||||| teclistamab (JNJ-64007957) / Genmab, J&J
Clinical: Teclistamab appeared to be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma, according to a phase I study presented at @ASCO #ASCO20. @szusmani @LevineCancer @AtriumHealth #mmsm https://t.co/3IJNQBwNwG (Twitter) - Jun 2, 2020
- |||| teclistamab (JNJ-64007957) / Genmab, J&J
WATCH: @szusmani, of @LevineCancer @AtriumHealth, discusses research with teclistamab (JNJ-64007957) in relapsed/refractory multiple myeloma. @ASCO #ASCO20 #mmsm https://t.co/ENsMcRsXRp (Twitter) - Jun 1, 2020
- | idecabtagene vicleucel (bb2121) / bluebird bio, BMS, teclistamab (JNJ-64007957) / Genmab, J&J, LCAR-B38M / J&J
JNJ4528 > teclistamab > bb2121 (Twitter) - May 31, 2020
- |||| CC-93269 / BMS, teclistamab (JNJ-64007957) / Genmab, J&J, AMG 420 / Amgen
Exciting results of teclistamab by @szusmani! 👍 ORR 67% in heavily pretx MM pt with long DoR even at low doses. 🙏 @myelomatom for 👍 discussion. AMG420 ORR 70%, CC93269 89% Need more data re: effectiveness of another BCMA directed tx once pt progresses through their first one. (Twitter) - May 31, 2020
- |||||| teclistamab (JNJ-64007957) / Genmab, J&J
Clinical: Something to chew on! Teclistamab BCMA-CD3 BiTE with impressive ORR 67% at top dose, heavily pre-tx'd population. I am most impressed with DOR, even at lower doses! Congrats to @szusmani and also @TomBmt133 for an excellent overview of this exciting technology #mmsm #ASCO20 (Twitter) - May 31, 2020
- |||| teclistamab (JNJ-64007957) / Genmab, J&J
Teclistamab Appears Safe at All Doses for Relapsed/Refractory Myeloma Treatment @szusmani @LevineCancer @AtriumHealth @ASCO #ASCO20 #mmsm https://t.co/a97FvKgnmB (Twitter) - May 30, 2020
- ||| teclistamab (JNJ-64007957) / Genmab, J&J
Teclistamab (BCMA x CD3); 83% triple-class refractory; at the highest dose, at least 78% response rate! Great presentation from our Saad! #ASCO20 @LevineCancer @szusmani (Twitter) - May 30, 2020
- || teclistamab (JNJ-64007957) / Genmab, J&J
Promising results for Teclistamab presented by @szusmani showing deepening of response in rel/ref MM #ASCO20 (Twitter) - May 30, 2020
- |||||| teclistamab (JNJ-64007957) / Genmab, J&J
Clinical: A great presentation on the safety and efficacy of teclistamab in real/ref #myeloma by @szusmani at #ASCO20. At the highest dose (270 mcg/kg) ORR 67% in triple-refractory patients. CRS mostly grade 1-2 ~60% #mmsm #Immunotherapy (Twitter) - May 30, 2020
- |||| teclistamab (JNJ-64007957) / Genmab, J&J
Excellent presentation by @szusmani on Teclistamab FIH data in RRMM. @ASCO #ASCO20 @ASTCT @MM_Hub @LevineCancer (Twitter) - May 30, 2020
- ||| teclistamab (JNJ-64007957) / Genmab, J&J
Saad Usmani @szusmani, MD, of @LevineCancer outlines the Phase 1 study investigating teclistamab in relapsed/refractory multiple myeloma #ASCO20 https://t.co/bziWteJDp7 (Twitter) - May 30, 2020
- ||| teclistamab (JNJ-64007957) / Genmab, J&J
Proud to be part of the phase 1 study of teclistamab in multiple myeloma with my colleagues at @PennCancer, presented today at #ASCO20 by @szusmani of @LevineCancer. Watch here: https://t.co/GDHrVIuQOB (Twitter) - May 30, 2020
- | teclistamab (JNJ-64007957) / Genmab, J&J
Teclistamab ohh exiting #ASCO20 (Twitter) - May 30, 2020
- |||||| teclistamab (JNJ-64007957) / Genmab, J&J
P1 data: CONGRESS | #ASCO20 | @szusmani, @LevineCancer presented data from the phase I study evaluating teclistamab, an anti-BCMA x CD3 bispecific antibody, for the treatment of R/R multiple #myeloma. Teclistamab appears tolerable across all doses and response rates increased with dose. (Twitter) - May 30, 2020
- |||| teclistamab (JNJ-64007957) / Genmab, J&J
Watching @szusmani present “live” on teclistamab in multiple myeloma in harnessing IO with novel approaches #ASCO2020 @LevineCancer (Twitter) - May 30, 2020
- |||||| teclistamab (JNJ-64007957) / Genmab, J&J
Clinical: As the #ASCO2020 Clinical Science Symposium goes live with my presentation on Teclistamab FIH data in RRMM, I will stay online @ASCO virtual platform to answer questions until 2:30 pm today and intermittently via twitter over the weekend #mmsm (Twitter) - May 30, 2020
- |||||| teclistamab (JNJ-64007957) / Genmab, J&J
Interview: #ASCO20 is starting and we’re ready to go! Watch this space for highlights from the event, including #Myeloma updates📊🎥 @VJHemOnc had a great chat w/ @szusmani on #Teclistamab & more! Interview coming shortly on 👉https://t.co/O9p0vDBrzw👈 @ASCO #MMsm #CTsm #ImmunoOnc #HemOnc (Twitter) - May 29, 2020
- || idecabtagene vicleucel (bb2121) / bluebird bio, BMS, teclistamab (JNJ-64007957) / Genmab, J&J, CC-92480 / BMS
Top MM #ASCO20 Abstracts Based on @Twitter Buzz 📌8500 (#CC92480): 94% Buzz 📌8503 (#BB2121): 94% 📌8501 (#BOSTON): 91% 📌8505 (#CARTITUDE-1): 88% 📌100 (#teclistamab): 83% 📌8504 (#EVOLVE): 74% 📌8606 (#STaMINA): 71% 📌LBA3 (#ENDURANCE): 70% Influencers: @mtmdphd & @VincentRK (Twitter) - May 27, 2020
- || idecabtagene vicleucel (bb2121) / bluebird bio, BMS, teclistamab (JNJ-64007957) / Genmab, J&J, CC-92480 / BMS
Top MM #ASCO20 Abstracts Based on @Twitter Buzz 📌8500 (#CC92480): 94% Buzz 📌8503 (#BB2121): 94% 📌8501 (#BOSTON): 91% 📌8505 (#CARTITUDE-1): 88% 📌100 (#teclistamab): 83% 📌8504 (#EVOLVE): 74% 📌8606 (#STaMINA): 71% 📌LBA3 (#ENDURANCE): 70% Influencers: @mtmdphd & @VincentRK (Twitter) - May 27, 2020
- | Tecvayli (teclistamab-cqyv) / Genmab, J&J
Trial primary completion date, IO biomarker: MajesTEC-1: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - May 20, 2020
P1, N=160, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Oct 2021 --> Jan 2022 Trial primary completion date: May 2020 --> Mar 2021
- teclistamab (JNJ-64007957) / Genmab, J&J
[VIRTUAL] A PHASE 1 STUDY OF TECLISTAMAB, A HUMANIZED B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) () - May 16, 2020 - Abstract #EHA2020EHA_525;
P1
Conclusion Teclistamab has a manageable safety profile across all doses explored. At the highest weekly treatment dose, a 78% overall response rate was observed in patients with advanced RRMM, supporting further evaluation of teclistamab in expansion cohorts.
- ||| JNJ-64007957 / Genmab, J&J, JNJ-61186372 / Genmab, J&J
In addition, 2 abstracts from the $JNJ #DuoBody program, #Amivantamab, anti-EGFR-cMET (JNJ-61186372), and #Teclistamab, BCMA x CD3 (JNJ-64007957) @Genmab $GMAB #ASCO20 (Twitter) - Apr 29, 2020
- | Darzalex Faspro (daratumumab/hyaluronidase) / J&J
Trial completion date, Trial primary completion date, Combination therapy: TRIMM-2: A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma (clinicaltrials.gov) - Apr 24, 2020
P1b, N=100, Recruiting, Sponsor: Janssen Research & Development, LLC
At the highest weekly treatment dose, a 78% overall response rate was observed in patients with advanced RRMM, supporting further evaluation of teclistamab in expansion cohorts. Trial completion date: May 2021 --> Oct 2021 | Trial primary completion date: Jan 2021 --> Oct 2021
- |||||| Darzalex IV (daratumumab) / J&J, JNJ-64007957 / Genmab, J&J
Preclinical: Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab https://t.co/e5apPBFRVU (Twitter) - Mar 29, 2020
- | Darzalex Faspro (daratumumab/hyaluronidase) / J&J
Enrollment open, Combination therapy: TRIMM-2: A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma (clinicaltrials.gov) - Mar 1, 2020
P1b, N=100, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: May 2021 --> Oct 2021 | Trial primary completion date: Jan 2021 --> Oct 2021 Not yet recruiting --> Recruiting
- teclistamab (JNJ-64007957) / Genmab, J&J
[VIRTUAL] Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM). () - Feb 27, 2020 - Abstract #ASCO2020ASCO_32;
P1
A 78% overall response rate was observed at the highest weekly treatment dose in pts with advanced RRMM, supporting further evaluation of teclistamab in expansion cohorts. Research Funding: Janssen R&D
- | Tecvayli (teclistamab-cqyv) / Genmab, J&J
Trial completion date, IO biomarker: MajesTEC-1: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 15, 2019
P1, N=160, Recruiting, Sponsor: Janssen Research & Development, LLC
Research Funding: Janssen R&D Trial completion date: Sep 2021 --> May 2021
- | Darzalex Faspro (daratumumab/hyaluronidase) / J&J
Trial completion date, Combination therapy: TRIMM-2: A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma (clinicaltrials.gov) - Oct 26, 2019
P1b, N=100, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Sep 2021 --> May 2021 Trial completion date: Feb 2022 --> Apr 2021
- | Tecvayli (teclistamab-cqyv) / Genmab, J&J
Trial completion date, Trial primary completion date, IO biomarker: MajesTEC-1: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 14, 2019
P1, N=160, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Feb 2022 --> Apr 2021 Trial completion date: Apr 2021 --> Sep 2021 | Trial primary completion date: Dec 2019 --> May 2020
- | Darzalex Faspro (daratumumab/hyaluronidase) / J&J
New P1 trial, Combination therapy: TRIMM-2: A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma (clinicaltrials.gov) - Sep 29, 2019
P1b, N=100, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | Tecvayli (teclistamab-cqyv) / Genmab, J&J
Enrollment change, Trial completion date, IO biomarker: MajesTEC-1: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 19, 2019
P1, N=160, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Apr 2021 --> Sep 2021 | Trial primary completion date: Dec 2019 --> May 2020 N=120 --> 160 | Trial completion date: Jun 2020 --> Apr 2021
- | Tecvayli (teclistamab-cqyv) / Genmab, J&J
Enrollment change, IO biomarker: MajesTEC-1: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 8, 2019
P1, N=120, Recruiting, Sponsor: Janssen Research & Development, LLC
N=120 --> 160 | Trial completion date: Jun 2020 --> Apr 2021 N=60 --> 120
- | Tecvayli (teclistamab-cqyv) / Genmab, J&J
Trial primary completion date, IO biomarker: MajesTEC-1: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 14, 2018
P1, N=60, Recruiting, Sponsor: Janssen Research & Development, LLC
N=60 --> 120 Trial primary completion date: Nov 2018 --> Dec 2019
- | Tecvayli (teclistamab-cqyv) / Genmab, J&J
Trial completion date, IO biomarker: MajesTEC-1: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 9, 2018
P1, N=60, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Nov 2018 --> Dec 2019 Trial completion date: Oct 2019 --> Jun 2020
- | Tecvayli (teclistamab-cqyv) / Genmab, J&J
Trial completion date, IO biomarker: MajesTEC-1: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 12, 2018
P1, N=60, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Oct 2019 --> Jun 2020 Trial completion date: Oct 2020 --> Oct 2019
- | Tecvayli (teclistamab-cqyv) / Genmab, J&J
Trial completion date, IO biomarker: MajesTEC-1: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 20, 2018
P1, N=60, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Oct 2020 --> Oct 2019 Trial completion date: Mar 2019 --> Oct 2020
- | Tecvayli (teclistamab-cqyv) / Genmab, J&J
Trial completion date, IO biomarker: MajesTEC-1: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 25, 2018
P1, N=60, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Mar 2019 --> Oct 2020 Trial completion date: Oct 2019 --> Mar 2019
- | Tecvayli (teclistamab-cqyv) / Genmab, J&J
Trial completion date, IO biomarker: MajesTEC-1: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 30, 2018
P1, N=60, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Oct 2019 --> Mar 2019 Trial completion date: Mar 2019 --> Oct 2019
- ||| Tecvayli (teclistamab-cqyv) / Genmab, J&J
Enrollment open, IO biomarker: MajesTEC-1: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 14, 2017
P1, N=60, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Mar 2019 --> Oct 2019 Not yet recruiting --> Recruiting
- ||| Tecvayli (teclistamab-cqyv) / Genmab, J&J
New P1 trial, IO biomarker: MajesTEC-1: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - May 9, 2017
P1, N=60, Not yet recruiting, Sponsor: Janssen Research & Development, LLC